The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2024 | Using MRD to accelerate drug approval in multiple myeloma
Karthik Ramasamy, MBBS, MRCP, FRCPath, PhD, Oxford University Hospitals NHS Foundation Trust, Oxford, UK, briefly discusses the value of measurable residual disease (MRD) as a diagnostic biomarker for clinical outcomes in multiple myeloma (MM) and comments on the positive implications of the recent Food and Drug Administration’s (FDA) Oncologic Drugs Advisory Committee (ODAC) meeting, during which an assessment was made on whether MRD should be used as a regulatory endpoint to accelerate the approval of novel therapies. This interview took place at the 64th Annual Scientific Meeting of the British Society for Haematology (BSH) congress in Liverpool, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
